SynthesisFrontiers in pharmacology2022
Nutraceuticals in the Modulation of the Intestinal Microbiota: Current Status and Future Directions.
Synthesis in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Risk of intestinal cancer in Crohn's disease: re-analysis and meta-regression of population-based cohort studies.Journal of Crohn's & colitis · 2026Pooled it
- Geraniol Treatment for Irritable Bowel Syndrome: A Double-Blind Randomized Clinical Trial.Nutrients · 2022Trial
- Integrating Traditional Chinese Medicine and Nanotechnology for Enhanced Management of Anti-Tumor Drug Toxicity.Molecules (Basel, Switzerland) · 2026Review
- Bioactive Compounds and their Therapeutic Potential in Gastrointestinal Disease.Current drug research reviews · 2026Review
- Positive Outcomes of Supplementation with Lecithin-Based Delivery Formulation ofLife (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pharmaceutical interest in the human intestinal microbiota has increased considerably, because of the increasing number of studies linking the human intestinal microbial ecology to an increasing number of non-communicable diseases. Many efforts at modulating the gut microbiota have been made using probiotics, prebiotics and recently postbiotics. However, there are other, still little-explored opportunities from a pharmaceutical point of view, which appear promising to obtain modifications of the microbiota structure and functions. This review summarizes all
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.